Diamyd Medical AB: 21-Month Findings from Diamyd® Type 1 Diabetes Trial to Be Presented at an International Diabetes Conference in Berlin
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announced today that preliminary findings from a 21-month follow-up analysis of the previously reported successful Phase II type 1 diabetes trial will be presented at the annual ISPAD (International Society for Pediatric and Adolescent Diabetes) meeting in Berlin, Germany, the 26th of September, 2007.